Early administration of vapreotide for variceal bleeding in patients with cirrhosis

被引:153
作者
Calés, P
Masliah, C
Bernard, B
Garnier, P
Silvain, C
Szostak-Talbodec, N
Bronowicki, J
Ribard, D
Botta-Fridlund, D
Hillon, P
Besseghir, K
Lebrec, D
机构
[1] CHU Angers, Serv Hepatogastroenterol, F-49033 Angers 01, France
[2] CHU Nantes, Serv Hepatogastroenterol, F-44035 Nantes 01, France
[3] CHU Pitie Salpetriere, Serv Hepatogastroenterol, Paris, France
[4] CHU La Reunion, Serv Hepatogastroenterol, La Reunion, France
[5] CHU Poitiers, Serv Hepatogastroenterol, Poitiers, France
[6] CHU Lille, Serv Hepatogastroenterol, F-59037 Lille, France
[7] CHU Nancy, Serv Hepatogastroenterol, Nancy, France
[8] CHU Nimes, Serv Hepatogastroenterol, Nimes, France
[9] CHU Marseilles, Serv Hepatogastroenterol, Marseille, France
[10] CHU Dijon, Serv Hepatogastroenterol, Dijon, France
[11] Univ Angers, Lab Hemodynam Splanchn, Angers, France
[12] Debiopharm, Lausanne, Switzerland
[13] Hop Beaujon, INSERM, U481, Clichy, France
[14] Hop Beaujon, Serv Hepatol, Clichy, France
关键词
D O I
10.1056/NEJM200101043440104
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: In patients with cirrhosis, pharmacologic or endoscopic treatment may control variceal bleeding. However, the effects of early administration of a somatostatin analogue followed by endoscopic treatment are unknown. Methods: We studied the effects of treatment with vapreotide, a somatostatin analogue, begun before endoscopic treatment in 227 patients with cirrhosis who were hospitalized for acute upper gastrointestinal bleeding. The patients were randomly assigned to receive vapreotide (a 50-mug intravenous bolus followed by an infusion at a rate of 50 mug per hour for five days) or placebo within a mean (+/-SD) of 2.3+/-1.5 hours after admission. The patients received endoscopic treatment a mean of 2.6+/-3.3 hours after the infusion was begun. After the exclusion of 31 patients whose bleeding was not caused by portal hypertension, there were 98 patients in each group. Results: At the time of endoscopy, active bleeding was evident in 28 of 91 patients in the vapreotide group (31 percent), as compared with 43 of 93 patients in the placebo group (46 percent, P = 0.03); in 12 patients endoscopy was either impossible or showed portal hypertensive gastropathy. During the five-day infusion, the primary objective - survival and control of bleeding - was achieved in 65 of 98 patients in the vapreotide group (66 percent) as compared with 49 of 98 patients in the placebo group (50 percent) (P = 0.02). The patients in the vapreotide group received significantly fewer blood transfusions (2.0+/-2.2 vs. 2.8+/-2.8 units, P = 0.04). Overall mortality rates at 42 days were not significantly different in the two groups. Conclusions: In patients with cirrhosis and variceal bleeding, the combination of vapreotide and endoscopic treatment is more effective than endoscopic treatment alone as a method of controlling acute bleeding. However, the use of combination therapy does not affect mortality rates at 42 days. (N Engl J Med 2001;344:23-8.) Copyright (C) 2001 Massachusetts Medical Society.
引用
收藏
页码:23 / 28
页数:6
相关论文
共 25 条
[1]  
Armitage P., 2001, STAT METHODS MED RES, V4th
[2]   SOMATOSTATIN OR OCTREOTIDE VERSUS ENDOSCOPIC SCLEROTHERAPY IN ACUTE VARICEAL HEMORRHAGE - A METAANALYSIS STUDY [J].
AVGERINOS, A ;
ARMONIS, A ;
RAPTIS, S .
JOURNAL OF HEPATOLOGY, 1995, 22 (02) :247-248
[3]   Two different doses and duration schedules of somatostatin-14 in the treatment of patients with bleeding oesophageal varices: a non-randomised controlled study [J].
Avgerinos, A ;
Viazis, N ;
Vlachogiannakos, J ;
Poulianos, G ;
Armonis, A ;
Manolakopoulos, S ;
Raptis, S .
JOURNAL OF HEPATOLOGY, 2000, 32 (01) :171-172
[4]   Early administration of somatostatin and efficacy of sclerotherapy in acute oesophageal variceal bleeds: the European acute bleeding oesophageal variceal episodes (ABOVE) randomised trial [J].
Avgerinos, A ;
Nevens, F ;
Raptis, S ;
Fevery, J ;
Armonis, A ;
Manolakopoulos, S ;
Poulianos, G ;
Tzathas, C ;
Katsaros, D ;
Soutos, D ;
Zacharopoulose, A ;
Adler, M ;
Bourgeois, N ;
Bac, DJ ;
VanBuuren, HR ;
Decruyenaere, J ;
Elewaut, A ;
Deman, M ;
Lepoutre, L ;
VanderSpek, P ;
Hautekeete, M ;
Reynaert, H ;
Buyse, M ;
Ritter, L ;
Burtin, B ;
Darcis, T ;
Ioannou, J ;
Natens, J ;
Natens, O .
LANCET, 1997, 350 (9090) :1495-1499
[5]   Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding:: A meta-analysis [J].
Bernard, B ;
Grangé, JD ;
Khac, EN ;
Amiot, X ;
Opolon, P ;
Poynard, T .
HEPATOLOGY, 1999, 29 (06) :1655-1661
[6]   SCLEROTHERAPY WITH OR WITHOUT OCTREOTIDE FOR ACUTE VARICEAL BLEEDING [J].
BESSON, I ;
INGRAND, P ;
PERSON, B ;
BOUTROUX, D ;
HERESBACH, D ;
BERNARD, P ;
HOCHAIN, P ;
LARRICQ, J ;
GOURLAOUEN, A ;
RIBARD, D ;
KARA, NM ;
LEGOUX, JL ;
PILLEGAND, B ;
BECKER, MC ;
DICOSTANZO, J ;
METREAU, JM ;
SILVAIN, C ;
BEAUCHANT, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (09) :555-560
[7]   RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF SOMATOSTATIN FOR VARICEAL BLEEDING - EMERGENCY CONTROL AND PREVENTION OF EARLY VARICEAL REBLEEDING [J].
BURROUGHS, AK ;
MCCORMICK, PA ;
HUGHES, MD ;
SPRENGERS, D ;
DHEYGERE, F ;
MCINTYRE, N .
GASTROENTEROLOGY, 1990, 99 (05) :1388-1395
[8]   SURVIVAL AND PROGNOSTIC INDICATORS IN COMPENSATED AND DECOMPENSATED CIRRHOSIS [J].
DAMICO, G ;
MORABITO, A ;
PAGLIARO, L ;
MARUBINI, E .
DIGESTIVE DISEASES AND SCIENCES, 1986, 31 (05) :468-475
[9]  
DAMICO G, 1995, HEPATOLOGY, V22, P332, DOI 10.1002/hep.1840220145
[10]  
de Franchis R, 1996, P 2 BAV INT CONS WOR